替罗非班在急性进展性脑梗死中应用-现代医学

替罗非班在急性进展性脑梗死中应用

单位：1. 安徽省阜阳市太和县人民医院神经内科, 安徽阜阳 236600;
2. 南京医科大学附属无锡市人民医院影像科, 江苏无锡 214023

分类号：R743.3

出版年·卷·期（页码）：2020·39·第八期（966-970）

摘要：

目的：探讨替罗非班联合阿司匹林、氯吡格雷对急性进展性脑梗死患者的临床疗效、生活质量ADL评分、神经功能缺损NIHSS评分的影响。方法：前瞻性分析90例急性进展性脑梗死患者，随机分为观察组和对照组，各45例。对照组给予服用阿司匹林、氯吡格雷治疗，观察组在经替罗非班联合治疗（24~72）h后贯续服用阿司匹林及氯吡格雷。比较2组患者治疗后临床疗效、NIHSS评分（24 h、72 h、7 d及14 d）、ADL评分及不良反应发生率。结果：观察组总有效率为88.99%，高于对照组的71.11%（P<0.05）；观察组治疗后NIHSS评分低于对照组，且观察组治疗后与治疗前ADL评分差值高于对照组（P<0.05）；不良反应发生率：观察组为13.85%，对照组为7.69%（P>0.05）。结论：替罗非班联合阿司匹林、氯吡格雷能有效地改善急性进展性脑梗死患者脑组织血流，提高患者生活质量，改善神经功能，安全性较好。

Objective: To study the clinical efficacy of tirofiban combined with aspirin and clopidogrel on scores of Daily Living Ability Scale(ADL) and National Institute of Health Stroke Scale (NIHSS) in patients with acute progressive cerebral infarction.Methods: 90 patients with acute progressive cerebral infarction admitted to our hospital from July 2018 to July 2019 were randomly divided into observation group andcontrol group(45 cases). The control group was treated with aspirin and clopidogrel, on top of which the observation group was given tirofiban. The clinical efficacy, ADL, NIHSS and adverse reactions between the two groups were statistically analyzed.Results: The total effective rate was 88.89% in the observation group, 71.11% in the control group (P<0.05). In the observation group, the NIHSS were lower than those during the time of 24 h, 72 h, 7 d and 14d,respectively (P<0.05) and meanwhile, the differentials of ADL between post treatment and prior treatment were high than those in the control group (P<0.05). The incidence of adverse reactions was 13.85% in the observation group, 7.69% in the control group(P > 0.05).Conclusion: Tirofiban combined with aspirin and clopidogrel has a curative effect in acute progressive cerebral infarction, improving the brain microcirculation blood flow and nerve function, enhancing life quality of patients, and ensuring the safety of the therapy.

参考文献：

[1] 李金艳.急性脑梗死溶栓治疗现状及药物研究进展[J].中国处方药,2017,15(4):8.
[2] HE X,LI D R,CUI C,et al.Clinical significance of serum MCP-1 and VE-cadherin levels in patients with acute cerebral infarction[J].European Review for Medical & Pharmacological Sciences,2017,21(4):804.
[3] 倪楚民,郭海森,蔡志雄,等.替格瑞洛、阿司匹林、替罗非班三联抗血小板药物联合阿托伐他汀钙用于急性ST段抬高型心肌梗死介入治疗的效果观察[J].现代中西医结合杂志,2018,27(35):3898.
[4] YU Y J,XIONG W.Tirofiban combined with rt-PA intraarterial thrombolysis improves the recanalization rate of acute middle cerebral artery occlusion in rabbits[J].European Review for Medical & Pharmacological Sciences,2018,22(9):288.
[5] 牛文书,刘扬,王玉斌,等.替罗非班在缺血性进展性卒中的疗效观察[J].中华疾病控制杂志,2019,28(4):38.
[6] 郝清卿,王立立,安少波,等.重组尿激酶原联合替罗非班在急性心肌梗死介入治疗中的作用[J].中国临床药理学杂志,2017,33(21):2098.
[7] 杨直堂,苏进营,刘志军,等.替罗非班在脑梗死不同时期的安全性及对血小板活化的影响[J].中国实用神经疾病杂志,2018,21(20):18.
[8] 彭斌,刘鸣,崔丽英,等.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,9(51):666.
[9] 缪中荣,王拥军,等.替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J].中国卒中杂志,2019,14(10):1034.
[10] WU Y,LI W,XIE X,et al.Endovascular treatment with tirofiban during the acute stage of cervical spinal cord infarction due to vertebral artery dissection[J].Journal of Spinal Cord Medicine,2018,29(7):1.
[11] 张建.大剂量阿托伐他汀联合替罗非班在急性心肌梗死患者PCI治疗中的应用效果[J].中国冶金工业医学杂志,2017,34(5):551.
[12] 陈绍春.阿托伐他汀联合替罗非班在急性心肌梗死治疗中的应用[J].中国医药指南,2018,16(28):86.
[13] SUGIYAMA T,XING L,YAMAMOTO E,et al.Thrombus resolution with tirofiban in the conservative management of patients presenting with plaque erosion[J].Coronary Artery Disease,2018,29(4):1.
[14] ZHAO H,ZHANG J,GU D,et al.Tirofiban facilitates the reperfusion process during endovascular thrombectomy in ICAS[J].Experimental & Therapeutic Medicine,2017,14(4):3314.
[15] 黄景欢.阿托伐他汀与替罗非班联用在急性心肌梗死中的临床效果[J].世界最新医学信息文摘,2017,29(33):95.
[16] PATRONO C.Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease:COMPASS in context.[J].Cardiovascular Research,2017,113(14):61.
[17] 张建坤,单微,张迎春,等.PCI术前给予替罗非班联合阿托伐他汀对急性心肌梗死患者外周血微RNA表达及血管内皮功能的影响[J].中国药房,2017,28(35):4952.
[18] LEE J I,GLIEM M,GERDES G,et al.Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke.[J].Plos One,2017,12(12):218.
[19] 杨豫伟.替罗非班联合阿托伐他汀对急性心肌梗死患者血清MMP-9、hs-CRP、NT-proBNP变化及预后的影响[J].河南医学研究,2017,26(11):1962.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录